VETMEDIN has been proven safe for over 15 years of worldwide use
Rigorous licensing studies demonstrated VETMEDIN is safe and well-tolerated1,2
- A 56-day field study involving 355 dogs confirmed the safety of VETMEDIN in dogs with congestive heart failure (CHF) due to atrioventricular valvular insufficiency (AVVI) or dilated cardiomyopathy (DCM) over a 2-month treatment period.
- An extended-use field study provided further evidence of VETMEDIN safety in dogs with CHF resulting from AVVI or DCM when used in combination with other appropriate CHF therapy for periods of at least 6 months.2
Common Side EffectsThe most commonly reported side effects of VETMEDIN were poor appetite, lethargy, diarrhea, dyspnea, azotemia, weakness, and ataxia. The prevalence of side effects was similar in the active control group (enalapril, an angiotensin-converting enzyme [ACE] inhibitor).
The incidence of new arrhythmias was also similar between the group treated with VETMEDIN and the enalapril-treated active control. Only 39.4% of dogs treated with VETMEDIN developed new arrhythmias versus 45% of active control dogs treated with the ACE inhibitor enalapril.
QUEST study confirms VETMEDIN safety3,4
- The international QUEST study was the largest study of its kind to be conducted in dogs with CHF. It studied 260 dogs in 11 countries over 3 years. Recently, investigators analyzed secondary endpoints more closely.
- VETMEDIN was well-tolerated and caused few adverse events.3
- Observed adverse events in both the VETMEDIN (n=18) and ACE inhibitor (n=17) groups were very similar.3
- Gastrointestinal disorders were most common (n=6 and 4, respectively), followed by abnormal behavior, such as lethargy, confusion, or uneasiness (n=3 and 4, respectively). Three dogs treated with VETMEDIN were reported to have had a seizure.
- VETMEDIN-treated dogs had less cardiac enlargement after therapy as demonstrated by significantly lower median vertebral heart score.4
Adverse events reported in VetSCOPE study were minimal
In the VetSCOPE trial, there were 3 adverse events in the VETMEDIN group and 1 in the ACE inhibitor group. Diarrhea, soft stool, and vomiting occurred in the VETMEDIN group (1 dog each) and colitis occurred in the ACE inhibitor group.
Proven track record of successful use worldwide
Veterinarians around the world have demonstrated VETMEDIN to be safe and effective for over 15 years. VETMEDIN was first licensed for use in dogs with CHF.2
Since then, more than 300 million doses of VETMEDIN have been sold in the USA, Europe, Australia, New Zealand, Canada, Mexico, South Africa, and Japan.5
In addition to proven use by practicing veterinarians in the US and around the world, positive experiences with VETMEDIN in clinical trials have been reported in peer-reviewed journals.3,6,7
Important safety information
VETMEDIN should not be given in case of hypertrophic cardiomyopathy, aortic stenosis, or any other clinical condition where an augmentation of cardiac output is inappropriate for functional or anatomical reasons.
The safety of VETMEDIN has not been established in dogs with:
- Asymptomatic heart disease
- Heart failure caused by etiologies other than atrioventricular valvular insufficiency or dilated cardiomyopathy
- Dogs younger than 6 months of age
- Dogs with congenital heart defects
- Dogs with diabetes mellitus or other serious metabolic diseases
- Dogs used for breeding or pregnant or lactating bitches
* All doses provided as tablets.